c reactive protein (crp) (201 206)

C-Reactive Protein (CRP) 201-206 acetate (C-Reactive Protein ) is the 201-206 fragment of C-Reactive Protein. C-Reactive Protein (CRP) acetate, the prototypic marker of inflammation, is a cardiovascular risk marker and may promote atherogenesis.

C-Reactive Protein (CRP) Fragment (201-206) is a peptide segment derived from C-Reactive Protein (CRP), the quintessential indicator of inflammation. As a cardiovascular risk marker, CRP may facilitate atherogenesis.

Protein Kinase C 19-31 acetate, a peptide inhibitor of protein kinase C (PKC), derived from the pseudo-substrate regulatory domain of PKCa (residues 19-31) with a serine at position 25 replacing the wild-type alanine, is used as protein kinase C substrate

Protein Kinase C Peptide Substrate acetate targets specific cell spacers ina manner that is dependent on second messengers and specific adaptor proteins in response to extracellular signals that activate g protein-coupled receptors, tyrosine Kinase recept

Activated Protein C (390-404), human acetate (Activated Protein C ) inhibits APC anticoagulant activity.

C-Reactive Protein (CRP) 77-82 acetate is the 77-82 fragment of C-Reactive Protein. C-Reactive Protein (CRP), the prototypic marker of inflammation, is a cardiovascular risk marker and may promote atherogenesis.C-reactive protein (CRP) is an annular (ring

C-Reactive Protein (CRP) 174-185 acetate is an acute phase serum protein synthesized in response to inflammatory cytokines, produces antitumor effects in animals. The fragment CRP (174-185) (RS-83277) shows similar activity by significantly enhancing the

CRP, an acute phase serum protein synthesized in response to inflammatory cytokines, produces antitumor effects in animals. The fragment CRP (174-185) (RS-83277) shows similar activity by significantly enhancing the tumoricidal activity of human monocytes

C-Reactive Protein (CRP) 77-82 is the 77-82 fragment of C-Reactive Protein. C-Reactive Protein (CRP), the prototypic marker of inflammation, is a cardiovascular risk marker and may promote atherogenesis.C-reactive protein (CRP) is an annular (ring-shaped)

Protein Kinase C (19-31) TFA, a peptide inhibitor of protein kinase C (PKC), derived from the pseudo-substrate regulatory domain of PKCa (residues 19-31) with a serine at position 25 replacing the wild-type alanine, is used as protein kinase C substrate p

Protein Kinase C (661-671), a fragment peptide of the β1 subspecies of Protein Kinase C (PKC), is instrumental in regulating cellular growth and has been implicated in tumor promotion [1] [2].

Protein Kinase C βII V5 peptide (660-673) (PKC βII (660-673)) exhibits an affinity for binding to RACK1 [1].

Protein Kinase C Peptide Substrate targets specific cell spacers ina manner that is dependent on second messengers and specific adaptor proteins in response to extracellular signals that activate g protein-coupled receptors, tyrosine Kinase receptors, or

Protein Kinase C (19-31), a peptide inhibitor of protein kinase C (PKC), derived from the pseudo-substrate regulatory domain of PKCa (residues 19-31) with a serine at position 25 replacing the wild-type alanine, is used as protein kinase C substrate pepti

Protein Kinase C (gamma) Peptide, a fragment of Protein Kinase Cγ, plays a role in dominant ataxia by inhibiting the nuclear import of aprataxin, which is associated with recessive ataxia [1].

Activated Protein C (390-404), human, a peptide derived from the vitamin K-dependent serine protease, effectively suppresses the anticoagulant activity of APC[1].

Protein Kinase C (alpha) Peptide (TFA) is a PKC-α-associated peptide functioning as a lipid-dependent serine/threonine protein kinase. It plays a pivotal role in regulating several cellular functions such as survival, proliferation, differentiation, migration, and adhesion [1].

Protein Kinase C (19-35) Peptide, serving as the PKC pseudosubstrate inhibitor/region, potentially inhibits PKC activity by obstructing the substrate-binding site within its kinase domain, rendering the cytoplasmic form of PKC inactive [1] [2].

Protein Kinase C (19-36) is a pseudosubstrate peptide inhibitor of protein kinase C (PKC), with an IC50 of 0.18 μM.

Protein Kinase C (19-31) TFA is a peptide inhibitor derived from the pseudo-substrate regulatory domain of PKCa (residues 19-31), featuring a serine substitution for alanine at position 25. It serves as a substrate peptide for evaluating Protein Kinase C (PKC) activity. PKC TFA plays a crucial role in modulating protein functions by phosphorylating the hydroxyl groups of serine and threonine amino acids on target proteins [1] [2].

Protein Kinase C (beta) Peptide, a fragment of Protein Kinase Cβ, is associated with hyperglycemia-induced decreases in endothelium-derived nitric oxide. Inhibiting Protein Kinase Cβ forestalls the impairment of endothelium-dependent vasodilation caused by acute hyperglycemia [1].

Protein Kinase C substrate, a specific substrate of Protein Kinase C, plays a pivotal role in signal transduction by facilitating the detection of protein through its enzyme's catalytic action on specific substrate phosphorylation [1].

The peptide region containing residues 390-404 in Activated Protein C (APC) is essential for anticoagulant activity and is available for interaction with antibodies or with other proteins, such as the macromolecular substrates Factors Va or VIIIa. APC reg